- Leap Therapeutics Inc ASCO GI 2024 DeFianCe Study Webcast TranscriptJan 23, 2024
- Leap Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Leap Therapeutics Inc at Robert W Baird Global Healthcare Conference TranscriptSep 13, 2023
- Leap Therapeutics Inc at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- Leap Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2023
- Leap Therapeutics Inc Acquires Flame Biosciences TranscriptJan 17, 2023
- Leap Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Leap Therapeutics Inc - R&D Day TranscriptJul 12, 2022
- Leap Therapeutics Inc ASCO GI 2022 DisTinGuish Study Conference Call TranscriptJan 21, 2022
- Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Leap Therapeutics Inc ESMO 2021 DisTinGuish Study Conference Call TranscriptSep 17, 2021
- Leap Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 14, 2021
- Leap Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 21, 2021
- Leap Therapeutics Inc DKN-01 Clinical Data Conference Call TranscriptMar 22, 2021
- Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Leap Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2020
- Leap Therapeutics, Inc. - Special Call TranscriptApr 23, 2020
- Leap Therapeutics, Inc. - Special Call TranscriptAug 06, 2019
Leap Therapeutics Inc ASCO GI 2024 DeFianCe Study Webcast Transcript
Good morning. Welcome to the Leap Therapeutics conference call to discuss new data from Part A of the DeFianCe study that was presented at the ASCO chat conference. (Operator Instructions)
I will now pass the conference call over to Cyndi Sirard, Chief Medical Officer of Leap Therapeutics. Cyndi?
Thank you, operator. Welcome and thank you to those of you joining us today for an update on Leap Therapeutics' DKN-01 development program. This call is being accompanied by a slide deck, so I will ask you to please turn to our forward-looking statements on slide 2.
I would like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the Risk Factors section of the company's most recent annual
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)